Modality
Vaccine
MOA
BCMA ADC
Target
CDK4/6
Pathway
Sphingolipid
CeliacMeso
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
Aug 2023
→ Jan 2028
Phase 1Current
NCT03431263
49 pts·Celiac
2023-08→2028-01·Not yet recruiting
49 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-031.8y awayPh2 Data· Celiac
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1/2
Not yet…
Catalysts
Ph2 Data
2028-01-03 · 1.8y away
Celiac
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03431263 | Phase 1/2 | Celiac | Not yet recr... | 49 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR |